Treatment of hepatitis C in solid organ transplantation

Susan E. Chan, Jonathan M. Schwartz, Hugo R. Rosen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) infection is highly prevalent worldwide, and results in significant morbidity and mortality. HCV frequently infects haemodialysis patients and appears to impact on long-term survival of kidney transplant recipients. Therefore, treatment is recommended for kidney transplant candidates before transplantation and should be avoided following transplantation because of a high risk of allograft rejection. HCV infection does not appear to influence survival in cardiac transplant recipients and cardiac transplant recipients should also not be treated. In general, HCV-infected patients with cirrhosis are not considered as candidates for either kidney or cardiac transplantation given their risk of decompensation. HCV is the most common indication for liver transplantation and re-infection with varying degrees of liver injury is universal. Survival after liver transplantation is reduced among HCV-infected patients when compared with uninfected controls. Therefore, treatment using interferon and ribavirin is advocated; however, such therapy is frequently limited by adverse effects. Thus, improved antiviral treatment modalities are eagerly awaited in the transplant setting.

Original languageEnglish (US)
Pages (from-to)489-498
Number of pages10
JournalDrugs
Volume64
Issue number5
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Transplantation (surgical)
Organ Transplantation
Hepatitis C
Transplants
Viruses
Hepacivirus
Liver
Virus Diseases
Liver Transplantation
Therapeutics
Transplantation
Kidney
Survival
Ribavirin
Heart Transplantation
Kidney Transplantation
Interferons
Antiviral Agents
Allografts
Renal Dialysis

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Treatment of hepatitis C in solid organ transplantation. / Chan, Susan E.; Schwartz, Jonathan M.; Rosen, Hugo R.

In: Drugs, Vol. 64, No. 5, 2004, p. 489-498.

Research output: Contribution to journalArticle

Chan, Susan E. ; Schwartz, Jonathan M. ; Rosen, Hugo R. / Treatment of hepatitis C in solid organ transplantation. In: Drugs. 2004 ; Vol. 64, No. 5. pp. 489-498.
@article{0b2e2da1c57c499ebc1d9bb46798ee9d,
title = "Treatment of hepatitis C in solid organ transplantation",
abstract = "Hepatitis C virus (HCV) infection is highly prevalent worldwide, and results in significant morbidity and mortality. HCV frequently infects haemodialysis patients and appears to impact on long-term survival of kidney transplant recipients. Therefore, treatment is recommended for kidney transplant candidates before transplantation and should be avoided following transplantation because of a high risk of allograft rejection. HCV infection does not appear to influence survival in cardiac transplant recipients and cardiac transplant recipients should also not be treated. In general, HCV-infected patients with cirrhosis are not considered as candidates for either kidney or cardiac transplantation given their risk of decompensation. HCV is the most common indication for liver transplantation and re-infection with varying degrees of liver injury is universal. Survival after liver transplantation is reduced among HCV-infected patients when compared with uninfected controls. Therefore, treatment using interferon and ribavirin is advocated; however, such therapy is frequently limited by adverse effects. Thus, improved antiviral treatment modalities are eagerly awaited in the transplant setting.",
author = "Chan, {Susan E.} and Schwartz, {Jonathan M.} and Rosen, {Hugo R.}",
year = "2004",
doi = "10.2165/00003495-200464050-00003",
language = "English (US)",
volume = "64",
pages = "489--498",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Treatment of hepatitis C in solid organ transplantation

AU - Chan, Susan E.

AU - Schwartz, Jonathan M.

AU - Rosen, Hugo R.

PY - 2004

Y1 - 2004

N2 - Hepatitis C virus (HCV) infection is highly prevalent worldwide, and results in significant morbidity and mortality. HCV frequently infects haemodialysis patients and appears to impact on long-term survival of kidney transplant recipients. Therefore, treatment is recommended for kidney transplant candidates before transplantation and should be avoided following transplantation because of a high risk of allograft rejection. HCV infection does not appear to influence survival in cardiac transplant recipients and cardiac transplant recipients should also not be treated. In general, HCV-infected patients with cirrhosis are not considered as candidates for either kidney or cardiac transplantation given their risk of decompensation. HCV is the most common indication for liver transplantation and re-infection with varying degrees of liver injury is universal. Survival after liver transplantation is reduced among HCV-infected patients when compared with uninfected controls. Therefore, treatment using interferon and ribavirin is advocated; however, such therapy is frequently limited by adverse effects. Thus, improved antiviral treatment modalities are eagerly awaited in the transplant setting.

AB - Hepatitis C virus (HCV) infection is highly prevalent worldwide, and results in significant morbidity and mortality. HCV frequently infects haemodialysis patients and appears to impact on long-term survival of kidney transplant recipients. Therefore, treatment is recommended for kidney transplant candidates before transplantation and should be avoided following transplantation because of a high risk of allograft rejection. HCV infection does not appear to influence survival in cardiac transplant recipients and cardiac transplant recipients should also not be treated. In general, HCV-infected patients with cirrhosis are not considered as candidates for either kidney or cardiac transplantation given their risk of decompensation. HCV is the most common indication for liver transplantation and re-infection with varying degrees of liver injury is universal. Survival after liver transplantation is reduced among HCV-infected patients when compared with uninfected controls. Therefore, treatment using interferon and ribavirin is advocated; however, such therapy is frequently limited by adverse effects. Thus, improved antiviral treatment modalities are eagerly awaited in the transplant setting.

UR - http://www.scopus.com/inward/record.url?scp=1542721929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542721929&partnerID=8YFLogxK

U2 - 10.2165/00003495-200464050-00003

DO - 10.2165/00003495-200464050-00003

M3 - Article

VL - 64

SP - 489

EP - 498

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 5

ER -